Drug Profile
Paxalisib - Kazia Therapeutics
Alternative Names: G-02441729; GDC-0084; RG 7666; SIM-0395Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Genentech
- Developer Alliance for Clinical Trials in Oncology; Dana-Farber Cancer Institute; Genentech; Global Coalition for Adaptive Research; Huntsman Cancer Institute; John Hopkins University; Kazia Therapeutics; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); St. Jude Childrens Research Hospital; University of California; Weill Cornell Medical College
- Class Amines; Antineoplastics; Morpholines; Oxazines; Purines; Pyrimidines; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors; Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Glioblastoma
- Phase II Brain metastases; Glioma; Lymphoma
- Phase I Diffuse intrinsic pontine glioma; Meningeal carcinomatosis
- Preclinical Malignant melanoma; Rhabdoid tumour
Most Recent Events
- 21 Mar 2024 Paxalisib licensed to SoVarGen Worldwide excluding China, Hong Kong, Macau, Taiwan
- 21 Mar 2024 Kazia Therapeutics in collaboration with SoVarGen plans a phase II trial for Partial epilepsies and Tuberous sclerosis in the latter half of 2024
- 13 Mar 2024 Pacific Pediatric Neuro-Oncology Consortium plans a clincal trial for Rhabdoid tumour (atypical teratoid) (Combination therapy, Second-line therapy or greater)